IJCS | Volume 31, Nº2, Março / Abril 2018

156 –0,2 –0,1 0,2 0 0,1 Favorece stent Favorece CRM Heterogeneidade: Chi 2 = 6,85, df = 7 (p = 0,44); I 2 = 0% Teste para efeito geral: Z = 2,58 (p = 0,010) Total events 435 353 Subtotal (IC95%) 4292 70,9% 4175 0,02 [0,00, 0,03] BEST 2015 28 437 22 440 7,3% 0,01 [–0,02, 0,04] CARDIa 2010 35 254 31 248 4,2% 0,01 [–0,05, 0,07] EXCEL 2010 71 913 53 903 15,2% 0,02 [–0,00, 0,04] FREEDOM 2012 114 894 83 859 14,7% 0,03 [0,00, 0,06] NOBLE 2016 36 592 33 592 9,9% 0,01 [–0,02, 0,03] PRECOMBAT 2011 17 279 23 275 4,6% –0,02 [–0,07, 0,02] SYNTAX LM 2009 123 871 92 805 14,0% 0,03 [–0,00, 0,06] LE MANS 2008 11 52 16 53 0,9% –0,09 [–0,26, 0,08] Estudo ou Subgrupo Stent Eventos Total Peso Diferença de Risco Diferença de Risco M-H, Fixo, IC95% CRM Eventos Total M-H, Fixo, IC95% Figura 3 – Mortalidade tardia: Stent versus cirurgia de revascularização miocárdica. O tamanho das caixas é proporcional ao numero de pacientes. As barras representam 95% de intervalo de confiança. O diamante representa a síntese dos resultados. CRM: cirurgia de revascularização miocárdica. SYNTAX: Synergy between PCI with Taxus and Cardiac Surgery; CARDia: Coronary artery revascularization in diabetic; Le Mans: Left main stenting; FREEDOM: Future Revascularization Evaluation in Patients with Diabetes Mellitus; Va-Cards: Coronary Artery Revascularization in Diabetes in VA Hospitals; BEST: Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease; PRECOMBAT: Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease; EXCEL: Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization; NOBLE: Nordic-Baltic- British Left Main Revascularization Study. Boldriot et al. 5 Gráfico obtido através do programa ReviewManager (RevMan). Version 5.3. –0,2 –0,1 0,2 0 0,1 Favorece stent Favorece CRM Heterogeneidade: Chi 2 = 7,53, df = 8 (p = 0,48); I 2 = 0% Teste para efeito geral: Z = 5,37 (p = 0,00001) Eventos totais 16 65 Subtotal (IC95%) 4204 70,5% 4184 –0,01 [–0,02, –0,01] Boudriot et al, 2011 0 100 2 101 –0,02 [–0,05, 0,01] CARDIa 2010 1 254 7 248 4,2% –0,02 [–0,05, –0,05] EXCEL 2010 5 948 12 948 15,9% –0,01 [–0,02, 0,00] FREEDOM 2012 3 953 16 947 16,0% –0,01 [–0,02, –0,00] NOBLE 2016 1 593 4 592 10,0% –0,01 [–0,01, 0,00] PRECOMBAT 2011 0 300 2 300 5,0% –0,01 [–0,02, 0,00] SYNTAX LM 2009 6 903 19 897 15,1% –0,01 [–0,03, –0,00] VA-CARDIS 2013 0 101 1 97 1,7% –0,01 [–0,04, 0,02] LE MANS 2008 0 52 2 54 0,9% –0,04 [–0,10, 0,02] Estudo ou Subgrupo Stent Eventos Total Peso Diferença de Risco Diferença de Risco M-H, Fixo, IC95% CRM Eventos Total M-H, Fixo, IC95% 1,7% Figura 4 – Acidente vascular encefálico: stent versus cirurgia de revascularização miocárdica. O tamanho das caixas é proporcional ao numero de pacientes. As barras representam 95% de intervalo de confiança. O diamante representa a síntese dos resultados. CRM: cirurgia de revascularização miocárdica. SYNTAX: Synergy between PCI with Taxus and Cardiac Surgery; CARDia: Coronary artery revascularization in diabetic; Le Mans: Left main stenting; FREEDOM: Future Revascularization Evaluation in Patients with Diabetes Mellitus; Va-Cards: Coronary Artery Revascularization in Diabetes in VA Hospitals; BEST: Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease; PRECOMBAT: Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease; EXCEL: Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization; NOBLE: Nordic-Baltic- British Left Main Revascularization Study. Boldriot et al. 5 Gráfico obtido através do programa ReviewManager (RevMan). Version 5.3. Andrade et al. Stent vs crm: metaanaálise de estudos randomizados Int J Cardiovasc Sci. 2018;31(2)152-162 Artigo Original